Valneva, a company created from the merger of Intercell AG of Austria and Vivalis SA of France, has raised €40 million in a share placement in order to support future vaccine and antibody product development. The offer was oversubscribed. ---Subscribe to MedNous to access this article--- Finance, Grants, Deals Company News
